NCT07055165 Connect2Care: Prostate Cancer Education and Screenings for African American Men
| NCT ID | NCT07055165 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oklahoma |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 466 participants |
| Start Date | 2025-07-26 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 466 participants in total. It began in 2025-07-26 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prostate cancer is the most diagnosed cancer in African American men and the second-leading cause of cancer-related death. The prostate-specific antigen (PSA) test is an early detection screening tool for prostate cancer, however, knowledge about prostate cancer and screening benefits and risks and uptake of PSA screening remains low among African American men. To address this inequity, this project proposes the use of the Connect2Care App to improve knowledge of prostate cancer, screening benefits, risks and increase readiness to complete a PSA test (e.g., intentions, motivation, confidence, and self-efficacy). The primary goal of this study is to evaluate the efficacy of the Connect2Care App in a 30-day randomized control trial compared to an existing app developed by the U.S. Department of Health \& Human Services (Prevention Taskforce App). African American men between the ages of 45 and 69 from Oklahoma (N = 266), who are not up to date with PSA screening according to recommended guidelines, will be randomly assigned 1:1 to receive either app. The app feasibility will be assessed: (1) efficacy, evaluated via post-intervention differences in knowledge of prostate cancer, screening benefits and risks, (2) app engagement and accessibility, measured via self-report validated questionnaires, and (3) app acceptability, explored via semi-structured qualitative interviews. We will explore readiness to complete a PSA test and identify predictors of readiness across both study arms. The successful demonstration of the feasibility of the Connect2Care App among African American men living in Oklahoma will support expanding this intervention to African American men nationwide.
Eligibility Criteria
Inclusion Criteria: * Live in Oklahoma * Self-identify as Black/African American * Self-identify as male * Between ages 45-69 * Not currently diagnosed with prostate cancer Exclusion Criteria: * Participants will be excluded if they are not interested in using a phone app for 30 days * Has taken a PSA test or has completed PSA screening within the past two years
Contact & Investigator
Jordan Neil, PhD
PRINCIPAL INVESTIGATOR
University of Oklahoma
Frequently Asked Questions
Who can join the NCT07055165 clinical trial?
This trial is open to male participants only, aged 45 Years or older, up to 69 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07055165 currently recruiting?
Yes, NCT07055165 is actively recruiting participants. Contact the research team at jordan-neil@ouhsc.edu for enrollment information.
Where is the NCT07055165 trial being conducted?
This trial is being conducted at Oklahoma City, United States.
Who is sponsoring the NCT07055165 clinical trial?
NCT07055165 is sponsored by University of Oklahoma. The principal investigator is Jordan Neil, PhD at University of Oklahoma. The trial plans to enroll 466 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.